Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.

Current opinion in oncology - 1 Mar 2012

Carter Corey A, Giaccone Giuseppe

Abstract excerpt

PURPOSE OF REVIEW: Testing for epidermal growth factor receptor (EGFR) mutations has become standard practice in treating patients with advanced nonsmall cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (TKIs) are being offered as first-line therapy in patients with EGFR activating mutations. These drugs offer an increased progression-free survival and response rate compared with standard chemotherapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 22314615
DOI: 10.1097/CCO.0b013e32834ec6a7
PMCID: PMC3277209

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.PMID 22314615Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.Semantic proximity Read ↗

Overcoming therapy resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.Semantic proximity Read ↗

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas.Semantic proximity Read ↗

Overcoming Resistance to EGFR Inhibitors in NSCLC.Semantic proximity Read ↗

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.Semantic proximity Read ↗

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationSemantic proximity Read ↗

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.Semantic proximity Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

The quest to overcome resistance to EGFR-targeted therapies in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.